The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer

• DOI: 10.1007/s00280-016-3026-6
• Publication Date: 2016-04-21T04:32:02Z
• Authors: Meiko Nishimura; Masanori Toyoda; Kei Takenaka; Yoshinori Imamura; Naoko Chayahara; Naomi Kiyota; Toru Mukohara; Takeshi Kotake; Akihito Tsuji; Kosuke Saito; Yoshiro Saito; Hironobu Minami
• Keywords: Adult; Male; Cancer Research; Administration, Oral; Toxicology; Deoxycytidine; Drug Administration Schedule; Erlotinib Hydrochloride; 03 medical and health sciences; 0302 clinical medicine; Gene Frequency; Japan; Antineoplastic Combined Chemotherapy Protocols; Humans; Pharmacology (medical); Neoplasm Metastasis; Infusions, Intravenous; HLA-B27 Antigen; Aged; Pharmacology; Aged, 80 and over; Middle Aged; 3. Good health; Pancreatic Neoplasms; Oncology; Original Article; Female; Lung Diseases, Interstitial; HLA-DRB1 Chains

In a phase III study of gemcitabine plus erlotinib for advanced pancreatic cancer conducted in Canada, the incidence interstitial lung disease (ILD) was 3.5 %. However, ILD reported as high 8.5 % Japanese II study. These results suggest influence ethnic factors association use with ILD. Here, we prospective to analyze relationship between human leukocyte antigen (HLA) alleles and patients receiving erlotinib. Patients were treated (1000 mg/m2; administered by intravenous infusion on days 1, 8, 15 every 4 weeks) (given orally at 100 mg/day). We compared frequencies HLA who did not develop A total 57 treated, (7.0 %) developed The combination HLA-B*15:01 DRB1*15:01 observed 2 (50 only 1 53 without (2 resulting odds ratio 52.0 (95 CI 3.2–842.5; p = 0.011). that is associated